Understanding how certain cells in ovarian cancer can promote tumor growth after treatment
Signaling basis of senescence-associated secretory phenotype and its implications in epithelial ovarian cancer
This study is looking at how certain cells in ovarian cancer can survive treatment and cause the cancer to come back, with the hope of finding new ways to target these tricky cells while keeping their helpful qualities, which could lead to better treatments for patients with ovarian cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10897891 on NIH RePORTER |
What this research studies
This research investigates how specific cells in epithelial ovarian cancer (EOC) can survive treatment and contribute to cancer relapse. It focuses on a phenomenon called the senescence-associated secretory phenotype (SASP), where these cells secrete factors that may help tumors evade the immune system. By exploring the mechanisms behind this process, the research aims to develop new therapies that can selectively target harmful aspects of these cells while preserving their tumor-suppressing qualities. Patients may benefit from innovative treatment strategies that could improve outcomes for those with EOC.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with epithelial ovarian cancer, particularly those with BRCA1/2 mutations.
Not a fit: Patients with non-epithelial ovarian cancers or those without BRCA mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that reduce the risk of cancer relapse in patients with epithelial ovarian cancer.
How similar studies have performed: Other research has shown promise in targeting the SASP in various cancers, suggesting that this approach may lead to significant advancements in treatment.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Zhang, Rugang — University of Tx Md Anderson Can Ctr
- Study coordinator: Zhang, Rugang
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.